中文簡(jiǎn)介

3 Biotech公布與生物技術(shù)研究和應(yīng)用相關(guān)的最新研究結(jié)果，以：-醫(yī)學(xué)和生物醫(yī)學(xué)科學(xué)-農(nóng)業(yè)-環(huán)境對(duì)這三個(gè)技術(shù)部門的關(guān)注認(rèn)識(shí)到，完整的生物技術(shù)應(yīng)用通常需要技術(shù)的結(jié)合。3生物技術(shù)不僅展示了生物技術(shù)的最新發(fā)展，還解決了為特定應(yīng)用集成各種技術(shù)的問題和好處。3生物技術(shù)呼吁學(xué)術(shù)界和工業(yè)界的科學(xué)家和工程師關(guān)注生物技術(shù)在醫(yī)藥、農(nóng)業(yè)和環(huán)境中的安全和有效應(yīng)用。歡迎各種生物技術(shù)應(yīng)用的文章，包括：-癌癥和干細(xì)胞研究-基因工程與克隆-生物修復(fù)與生物降解-生物信息學(xué)與系統(tǒng)生物學(xué)-生物標(biāo)志物和生物傳感器-生物多樣性和生物發(fā)現(xiàn)-生物機(jī)器人和生物毒素-分析生物技術(shù)與人類基因組3生物技術(shù)公司接受原創(chuàng)和評(píng)論文章，以及簡(jiǎn)短的研究報(bào)告、方案和方法、給編輯的注釋、給編輯的信件和出版的書評(píng)。還將考慮最新的專題評(píng)論文章。所有的手稿都經(jīng)過同行評(píng)審，以獲得科學(xué)的質(zhì)量和認(rèn)可。3生物技術(shù)公司最近收到了其第一個(gè)影響因素，目前涵蓋了一系列A&I服務(wù)，包括：-科學(xué)引文索引擴(kuò)展-期刊引文報(bào)告/科學(xué)版-生物文摘-Biosis預(yù)覽3生物科技在連續(xù)文章出版（cap）下出版，在收到作者證明后不久，接受的論文將以卷和文章編號(hào)在線出版。CAP旨在加快從接收文章到最終出版的過程，而不需要將文章放置在等待隊(duì)列中。這將確保3個(gè)生物技術(shù)的所有文章都能立即提供給相關(guān)索引和抽象數(shù)據(jù)庫的研究人員。

投稿網(wǎng)址：https://www.editorialmanager.com/BITC

英文簡(jiǎn)介

3 Biotech publishes the results of the latest research related to the study and application of biotechnology to:- Medicine and Biomedical Sciences- Agriculture- The EnvironmentThe focus on these three technology sectors recognizes that complete Biotechnology applications often require a combination of techniques. 3 Biotech not only presents the latest developments in biotechnology but also addresses the problems and benefits of integrating a variety of techniques for a particular application. 3 Biotech appeals to scientists and engineers in both academia and industry focusing on the safe and efficient application of Biotechnology to Medicine, Agriculture and the Environment.Articles from a huge variety of biotechnology applications are welcome including:- Cancer and stem cell research- Genetic engineering and cloning- Bioremediation and biodegradation- Bioinformatics and system biology- Biomarkers and biosensors- Biodiversity and biodiscovery- Biorobotics and biotoxins- Analytical biotechnology and the human genome3 Biotech accepts original and review articles as well as short research reports, protocols and methods, notes to the editor, letters to the editor and book reviews for publication. Up to date topical review articles will also be considered. All the manuscripts are peer-reviewed for scientific quality and acceptance.3 Biotech has recently received its first Impact Factor and is now covered by a range of A&I services, including:- Science Citation Index Expanded- Journal Citation Reports/Science Edition- Biological Abstracts- BIOSIS Previews3 Biotech publishes under the Continuous Article Publishing (CAP) in which accepted papers are published online with volume and article numbers shortly after receipt of authors proofs. CAP aims to speed up the process from acceptance of articles to final publication without the need for articles to be placed in a waiting line. This will ensure that all articles in 3 Biotech are immediately available for researchers in relevant indexing and abstracting databases.